verified SJR 3,609 · Q1 • database Scopus / SJR & Web of Science indexed

United States · Mary Ann Liebert Inc.

workspace_premium Q1 — Medicine (miscellaneous) lock Subscription

Diabetes Technology and Therapeutics

Diabetes Technology and Therapeutics is a journal indexed in SJR in Medicine (miscellaneous) and Endocrinology with an H index of 109. It has an SJR impact factor of 3,609 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 3,609.

Diabetes Technology and Therapeutics focuses its scope in these topics and keywords: diabetes, type, patients, mellitus, glucose, health, nutritional, distress, efficacy, emptying, ...

ISSN: 1520-9156

Publisher: Mary Ann Liebert Inc.

Category: Medicine (miscellaneous)

Indexation: verifiedScopus / SJR verifiedWeb of Science

open_in_new Portal NPD menu_book Guidelines NPD

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

3,609 Q1

H-index 109

Acceptance rate pie_chart

25% Selective

Source Acceptance_Rate

Time to publication hourglass_top

NPD

Field NPD

Publication cost (APC) payments

NPD Subscription

Non-OA path NPD

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

3,609

H-index

109

Docs (year)

164

Docs 3y

430

Total refs

4913

Cites 3y

2561

Citable 3y

383

Cites/Doc 2y

5.87

Ref/Doc

29.96

Immediate OA

—

Embargoed OA

NPD

Non OA / Submission

—

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

American Dietetic Association Guide to Eating Right When You Have Diabetes

Who Is Downloading the Free AIDA v4.3a Interactive Educational Diabetes Computer Software? A 1-Year Survey of 3,864 Downloads

British Diabetic Association Review of the AIDA v4 Diabetes Software Simulator Program

Bioenergetics of Animal Locomotion: Lessons for Expedient Monitoring in Human Fitness and Weight Management

Analysis:The Role of New Technology in the Early Detection of Hypoglycemia

Analysis: The Suboptimal Roadmap to the Intensive Therapy Target

Analysis: Signs of Illness: When Will Technology Provide Greater Advantage Than the Practiced Eye of the Clinician (or the Military Commander)?

Analysis: PENDRA: The Once and Future Noninvasive Continuous Glucose Monitoring Device?

Analysis: Novel Biosensors for Long-Term In Vivo Physiological Monitoring

Analysis: Lessons on Developing a Better Basal Insulin

Analysis: Home Fructosamine Testing: Is Its Demise Premature?

Analysis: A Nurse Educator's Perspective on the Innovo¬Æ Insulin Delivery System

SHOW MORE ARTICLES

An Overview of Human Factors Engineering at CDRH in the Safety and Effectiveness of Blood Glucose Meters

"A Clinician's Perspective on Some of the Challenges in ""Closing the Loop"

Alternative Site Blood Glucose Testing: A Multicenter Study

Algorithmic Evaluation of Metabolic Control and Risk of Severe Hypoglycemia in Type 1 and Type 2 Diabetes Using Self-Monitoring Blood Glucose Data

Alarms Based on Real-Time Sensor Glucose Values Alert Patients to Hypo- and Hyperglycemia: The Guardian Continuous Monitoring System

Actigraphy as Metabolic Ethography: Measuring Patterns of Physical Activity and Energy Expenditure

Accessibility of Insulin Pumps for Blind and Visually Impaired People

A Prospective, Randomized, Multicentered Controlled Trial to Compare the Annual Outcomes of Patients with Diabetes Mellitus Monitored with Weekly Fructosamine Testing Versus Usual Care: A 3-Month Interim Analysis

A Continuous Glucose Sensor Based on Wired Enzyme‚Ñ¢ Technology - Results from a 3-Day Trial in Patients with Type 1 Diabetes

A 2-Year Pilot Trial of Continuous Subcutaneous Insulin Infusion Versus Intensive Insulin Therapy in Patients with Newly Diagnosed Type 1 Diabetes (IMDIAB 8)

"It Is Definitely a Game Changer": A Qualitative Study of Experiences with In-home Overnight Closed-Loop Technology Among Adults with Type 1 Diabetes

"Is Angiotensin I-Converting Enzyme a ""Master"" Disease Gene?"

FAQs

Diabetes Technology and Therapeutics has an SJR of 3,609 (best quartile Q1) in the CountryOfPapers database.

Immediate OA APC is not available (NPD).

The acceptance rate recorded for Diabetes Technology and Therapeutics is 25%.

Diabetes Technology and Therapeutics

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of Diabetes Technology and Therapeutics?

What is the APC / publication cost?

What is the acceptance rate?